gls4
Small moleculeexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jul 26, 2017 (NCT03638076)
Timeline
Indications
Mechanism of action
- Hepatitis B virusINHIBITOR
Hepatitis B virus inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04551261 | Phase 1 | Nov 1, 2020 | Sunshine Lake Pharma Co., Ltd. |
| NCT04147208 | Phase 2 | Feb 28, 2019 | Jilin University, Sunshine Lake Pharma Co., Ltd. |
| NCT03662568 | Phase 1 | Jun 26, 2018 | Jilin University, Sunshine Lake Pharma Co., Ltd. |
| NCT03638076 | Phase 2 | Jul 26, 2017 | Jilin University, Sunshine Lake Pharma Co., Ltd. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sunshine Lake Pharma Co., Ltd. | For profit | 4 | 4 | 2 | 2017 |
| Jilin University | Academic/Hospital | 3 | 0 | 2 | 2017 |
2 organizations
Page 1 / 1